Which key enzyme in the cholesterol synthesis pathway is inhibited *in vitro* by specific lipids like MGDGs and DGDGs isolated from taro flour derivatives?
Human lanosterol synthase
Taro demonstrates a multifaceted impact on heart health, extending beyond potassium and fiber to include specific lipid-modulating compounds found in its flour derivatives. Research has shown that certain lipids extracted from taro, namely monogalactosyldiacylglycerols (MGDGs) and digalactosyldiacylglycerols (DGDGs), exhibit an ability to inhibit human lanosterol synthase when tested *in vitro*. Lanosterol synthase holds a significant role because it is a critical enzyme in the pathway responsible for cholesterol synthesis within the body. Targeting this enzyme is a common molecular strategy utilized by pharmaceutical agents designed to manage high cholesterol, indicating a natural pathway in taro that supports healthy lipid management.
